Table II.

Recommended Screening and Preventative Care for Specific Late Effects

Late Effects	Screening and Preventative Care at Specific Time-points
Prolonged Cytopenia	CBC with differential at least every 30 days after the acute phase of CAR T cell infusion until normalization of blood counts
Hypogammaglobulinemia	Obtain serum IgG level monthly beyond day 30 after CAR T-cell infusion, until IgG>400 mg/dl. Consider obtaining IgG subclass level if active infections despite total IgG>400 mg/dl
Neuropsychiatric Late effects	Clinical evaluation for signs and symptoms of neuropsychiatric dysfunction monthly after day 30, with diagnostic tests [e.g. objective neuropsychological testing, MRI] in patients with signs or symptoms
Immune-related Adverse Events	Clinical evaluation for signs or symptoms of immune-relate adverse events such as pneumonitis or colitis at least every month until one year and every six months thereafter and targeted diagnostic tests in those with clinical suspicion
Second Cancer	Age and sex-appropriate screening for solid cancers Periodic monitoring of blood counts to screen for therapy-related myeloid neoplasms and low threshold to perform bone marrow examination in patients with unexplained or worsening cytopenia
Late Infections	CDC panel for CD4+ T-cell count monthly beyond day 30 until CD4 count is greater than 200 cells/μL

Note: Management recommendations in this table are based on current state of evidence and expert opinion.